Status:
ENROLLING_BY_INVITATION
Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study
Lead Sponsor:
Wayne State University
Collaborating Sponsors:
Barbara Ann Karmanos Cancer Institute
Conditions:
PTSD
Suicidal Thoughts and Behaviors
Eligibility:
All Genders
19-69 years
Brief Summary
This study will be the first to use brain imaging to explore how cannabis affects the brain and inflammation in U.S. military veterans with PTSD. It builds on an ongoing study testing different combin...
Detailed Description
This study, referred to here as the 'Neuroimaging Study,' is a supplement (add-on) to our ongoing VMR study (Wayne State Warriors Marijuana Clinical Research Program: Investigating the Impact of Canna...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Eligible for, and provided written informed consent to participate in, the Parent Study (NCT06381180) and to be contacted regarding 'future research studies.'
- Able/willing to provide written informed consent to participate in the Neuroimaging Study.
- Exclusion Criteria (eligible if the subject does not meet both criteria):
- Contraindications for MRI scanning include, but are not limited to: as braces, pacemaker, implanted metal (self-report MR screening form and ferromagnetic detectors) or medical conditions that prevent comfortable MRI scanning procedures, e.g., inability to lay supine for 60 minutes, claustrophobia, or body weight \> 275lbs.
- Contraindications for PET \[18F\]FETrp imaging include, but are not limited to: chronic medical conditions that alter radiotracer pharmacokinetic properties, e.g, Diabetes I/II (or uncontrolled glucose levels \[\>200mg/dl non-fasting\]), abnormal BMI (\<18.5 or \> 35kg/m2), autoimmune diseases, or other chronic inflammatory conditions, or take medications (3+ days/week) that will alter radiotracer binding, e.g., glucose stabilizing medications, proton-pump inhibitors, or anti-inflammatory agents, or have medical conditions that prevent comfortable PET scanning procedures, e.g., inability to lay supine for \~75 minutes, tolerate a radial vein catheter and up to 35ml of whole blood drawn, or body weight \> 275lbs.
Exclusion
Key Trial Info
Start Date :
November 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2030
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07222306
Start Date
November 1 2025
End Date
August 31 2030
Last Update
October 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tolan Park Medical Building
Detroit, Michigan, United States, 48201